Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

A phase 3 clinical trial has shown that adding a targeted immunotherapy drug to chemotherapy dramatically improved – almost ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

HER2 negative means your breast cancer tissue ... They will also test whether your cancer cells have hormone receptors in them. If they do, hormone-blocking therapies may be prescribed first.

AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

In-Depth Market Assessment : A detailed market analysis of the HR+ HER2-negative Breast Cancer domain was included, covering pipeline insights and the projected launch timelines of emerging therapies.

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.